Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15319
UPID:
PO4F3_HUMAN
Alternative names:
Brain-specific homeobox/POU domain protein 3C
Alternative UPACC:
Q15319; O60557; Q2M3F8
Background:
POU domain, class 4, transcription factor 3, also known as Brain-specific homeobox/POU domain protein 3C, plays a pivotal role in auditory system development. It functions as a transcriptional activator by binding to octamer motifs in target gene regulatory regions, crucial for hair cell differentiation in the inner ear.
Therapeutic significance:
Linked to Deafness, autosomal dominant, 15, this protein's mutation affects gene expression, leading to non-syndromic hearing loss. Understanding its role could pave the way for innovative hearing loss therapies.